Podcast on Vascular Anomalies: Classification, Diagnosis, and Management

Kapitoly

Zmatky v terminologii

Nová klasifikace

Nádory versus malformace

The Vanishing Tumor

A Three-Act Drama

What Doctors See

When Skin Breaks Down

Steroids and Propranolol

The Aggressive Tumor: KHE

Born This Way

Laser Treatment Timing

Outcomes and Red Flags

What is an LM?

Diagnosis and Dangers

Sclerotherapy First

When Surgery is the Answer

Sclerotherapy First

A Vascular Short-Circuit

Symptoms and Staging

The Slow-Flow Syndrome

The Fast-Flow Counterpart

What is PHTS?

Diagnosis and Key Signs

Přepis

Sam: …počkej, takže lékaři si po staletí mysleli, že mateřská znaménka způsobuje strava matky? Třeba když jedla příliš mnoho jahod?

Sara: Přesně tak! Vážně se používaly názvy jako „jahodové“ nebo „portské víno“. Odráželo to starou víru, ne vědu. Vítejte u Studyfi Podcast.

Sam: To je neuvěřitelné. Takže jak se v tom konečně udělal pořádek?

Sara: No, dlouho to byl chaos. I když se v 19. století pokusil o klasifikaci patolog jménem Virchow, jeho termíny byly matoucí. Používal stejný název pro útvary, které mizí, a pro ty, které nikdy nezmizí.

Sam: Takže to muselo vést ke spoustě špatných diagnóz.

Sara: Přesně. Bylo to nelogické. Zásadní změna přišla až v roce 1982 s novým biologickým klasifikačním systémem. Ten konečně vnesl do terminologie jasno.

Sam: Dobře, takže v čem spočívá ten klíčový rozdíl? Jak to zjednodušili?

Sara: Rozdělili anomálie do dvou hlavních kategorií, a to je nejdůležitější si zapamatovat: cévní nádory a cévní malformace. Dvě naprosto odlišné věci.

Sam: Nádory a malformace. Jaký je mezi nimi hlavní rozdíl?

Sara: Přemýšlejte o tom takhle. Nádory jsou neoplastické, což znamená, že se v nich množí buňky, konkrétně endotelové buňky. Rostou rychle, ale často se pak samy zmenšují nebo mizí, jako třeba infantilní hemangiom.

Sam: Aha, takže ty rostou a pak zase ustupují. A co malformace?

Sara: Malformace jsou chyby ve vývoji cév už během embryonálního období. Jsou přítomné při narození, i když nemusí být hned vidět, a rostou pomalu spolu s dítětem. Nikdy samy nezmizí.

Sam: Takže shrnuto: nádory mají aktivní růst buněk a mohou involvovat, kdežto malformace jsou strukturální chyby, které zůstávají. To dává smysl. Přesuňme se teď k...

Sam: So, that clarifies the structural issues of vascular malformations. But what about the other side of that coin? Things like infantile hemangiomas?

Sara: Great question. That's where we get into vascular *tumors*. And the infantile hemangioma, or IH, is the most common one. It's a benign endothelial tumor.

Sam: Benign tumor... but the key thing that makes it so different is its life cycle, right?

Sara: Exactly! It has this unique biologic behavior. It grows rapidly, then it slowly regresses on its own, and it never comes back.

Sam: So it just... packs its bags and leaves? Wish my acne did that in high school.

Sara: Wouldn't that be nice? But yes, think of it that way. This is why getting the diagnosis right is so critical. For years, the terminology was a mess.

Sam: How so?

Sara: People would use the word “hemangioma” as a catch-all term for totally different lesions. Here's the most common mistake: there’s no such thing as a “cavernous hemangioma.”

Sam: Really? I feel like I've heard that term everywhere.

Sara: I know! But that lesion is actually either a deep infantile hemangioma or a venous malformation. They are completely different biologically.

Sam: So how do we tell them apart for sure?

Sara: We have amazing tools now. There's a marker called GLUT1. It’s an immunohistochemical marker that acts like a specific name tag. It only shows up on infantile hemangiomas.

Sam: A biological ID card. That's clever. So once we've identified it... what happens during that growth phase you mentioned?

Sam: So that explains the underlying biology, but what does this mean for a newborn? How does a hemangioma actually behave? It’s not just a static spot, right?

Sara: Not at all! It has a very dramatic life cycle. Think of it in three acts. First is the proliferating phase, from birth to about one year.

Sam: Proliferating... so, growing?

Sara: Exactly. And growing *fast*! It often grows much faster than the baby. This is when it gets that classic bright red, "strawberry mark" look if it's on the surface.

Sam: And then what happens? It can’t just grow forever.

Sara: Nope. After about a year, it enters the involuting phase. It hits a plateau, the growth stops, the color starts to fade, and the lesion flattens. This can last until the child is about four years old.

Sam: So it puts on a big show and then just slowly exits the stage.

Sara: That's the perfect way to put it! The final act is the involuted phase, where most of the tumor is replaced by fibrofatty tissue.

Sam: Does it always disappear without a trace then?

Sara: Not always. About half the time, there can be some residual signs. Things like scarring, maybe some tiny leftover blood vessels, or just some saggy skin.

Sam: So how common are these? Are we talking one in a million?

Sara: Oh, much more common. It occurs in about 4-5% of Caucasian infants. And it's four times more common in girls than boys!

Sam: Wow, that's a huge difference. So this predictable life cycle is the key to diagnosis?

Sara: It's a huge clue. The rapid growth followed by slow involution is really characteristic. It's what separates it from other vascular issues.

Sam: So to recap, it appears, grows like crazy for a year, then spends the next few years shrinking. That’s a pretty unique pattern.

Sara: It really is. But sometimes, where it appears on the body can cause major problems, which I think is what we should dive into next.

Sam: So, it's not just a 'wait and see' situation then. What are the actual treatment options if a hemangioma becomes problematic?

Sara: Exactly. Management can range from simple wound care to systemic medication, depending on the lesion's size, location, and behavior.

Sam: Okay, so what's the most common issue you see?

Sara: Ulceration is a big one. The skin over the hemangioma is fragile and can break down, especially in high-friction areas like the neck or diaper area.

Sam: That sounds painful for a baby.

Sara: It can be. The goal is prevention... keeping the skin moisturized. If an ulcer does form, it's about gentle washing and sometimes topical antibiotics to prevent infection.

Sam: And for more aggressive tumors? What can actually shrink them?

Sara: For smaller, tricky spots—like on an eyelid—we can inject corticosteroids directly. This stabilizes growth in almost all cases and shrinks about 75% of them.

Sam: And for the really large, problematic ones?

Sara: Then we move to oral medications. For decades, the standard was oral prednisolone, a corticosteroid. It’s very safe and effective.

Sam: I see. So it's a reliable choice.

Sara: Very. More recently, a heart medication called propranolol has also proven effective. But it’s newer and can have some serious side effects, so it requires much closer monitoring.

Sam: So it’s a trade-off between a long history of safety and a newer option with more potential risks?

Sara: That’s a great way to put it. The choice really depends on the specific child and the tumor. It’s a careful risk-benefit analysis every time.

Sam: It’s amazing there are so many tools in the toolbox. But what about lasers or even surgery? When do those come into play?

Sam: Okay, so besides the more common types, what other vascular tumors should we know about?

Sara: Great question. Let's talk about a rare one called Kaposiform Hemangioendothelioma, or KHE.

Sam: That's a mouthful! What makes KHE so unique?

Sara: Well, it's locally aggressive, meaning it can invade nearby tissues, but thankfully it doesn't metastasize to distant parts of the body.

Sam: So it's a neighborhood bully, not a world traveler.

Sara: Perfect analogy! But here’s the really critical part. Over half of patients with KHE get something called Kasabach-Merritt phenomenon, or KMP.

Sam: Okay, that sounds serious.

Sara: It is. The tumor basically traps platelets, leading to dangerously low counts. This can cause severe bleeding. It's a life-threatening complication.

Sam: Wow. So how do you treat it? You can't just cut it out?

Sara: Usually not, they're too extensive. The first-line therapy is actually a drug called vincristine, which has a fantastic 90% response rate.

Sam: So, some of these are present at birth. Are there others that are fully formed right from day one?

Sara: Yes, those are called congenital hemangiomas. They don't have that postnatal growth spurt we see in others. They are fully grown at birth.

Sam: So they come in two main types, right?

Sara: Exactly. First, you have RICH—Rapidly Involuting Congenital Hemangioma. As the name suggests, it involutes, or shrinks, really fast. Most are gone by 14 months.

Sam: And the other one?

Sara: That would be its stubborn twin, NICH—Non-involuting Congenital Hemangioma. It doesn't regress. It just... stays.

Sam: So for RICH you just wait, but for NICH you might consider surgery later on to improve its appearance.

Sara: You've got it. It's a classic case of watching and waiting versus taking action. Now, this all connects back to how these vessels form in the first place, which is a whole other fascinating story.

Sam: So that makes sense for those deeper malformations. But what about the more common ones, the capillary malformations?

Sara: Right, the ones people often call port-wine stains. The go-to treatment here is the pulse-dye laser.

Sam: A laser! Sounds very sci-fi.

Sara: It kind of is! And here's the key part—starting treatment early is a game-changer.

Sam: Why is it so important to start early, like in infancy?

Sara: Two big reasons. First, the laser works better on younger, thinner skin, so you get superior results. And second, it reduces the risk of the lesion darkening or thickening over time.

Sam: That's fascinating. So you treat them before the child can even remember it.

Sara: Exactly. For infants, we can often do it while they're awake with just a topical anesthetic. Once they're toddlers, they don't hold still, so general anesthesia is usually needed.

Sam: I can only imagine trying to get a toddler to hold still for a laser.

Sara: It's not happening. The good news is that adolescents and adults can usually tolerate it while awake. It just takes multiple sessions.

Sam: Is it always successful?

Sara: It varies. The head and neck respond best. About 15% of patients see almost complete lightening, while another 65% get significant improvement. But for about 20%, it doesn't respond well.

Sam: And I read that sometimes a CM can be a sign of something else going on?

Sara: Yes, that's a critical point. A CM over the spine, for example, can be a red flag for issues like a tethered spinal cord.

Sam: So it's not always just a skin-deep issue.

Sara: Correct. That's why a thorough diagnosis is so important before just jumping to treatment. Now, this connects directly to venous malformations, which have their own set of challenges...

Sam: And that makes a lot of sense for the venous side. So, let's switch gears a bit. What about the lymphatic system? What are lymphatic malformations, or LMs?

Sara: Great question! Think of them as soft, compressible masses. They're most common on the head and neck. Sometimes the skin over them looks normal, but other times it can have a bluish tint or even be covered in little pink vesicles.

Sam: Vesicles? Like tiny blisters?

Sara: Exactly. And those can cause issues. The two biggest complications with LMs are bleeding and infection. Infection is a huge deal—it can progress to sepsis really fast.

Sam: Wow, that's serious. Are there other complications besides infection?

Sara: Absolutely. They can cause bony overgrowth. The jaw is a common spot, which can lead to dental problems like an open bite. And depending on where they are, they can really impact a person's life, especially with vision or even breathing.

Sam: So how are they diagnosed? Is it some complex test?

Sara: Here's the surprising part... about 90% are diagnosed just from the patient's history and a physical exam.

Sam: No kidding? So the doctor just kind of... pokes it and goes "yep, that's an LM"?

Sara: You're not far off! For small, superficial ones, that's often enough. For larger or deeper ones, an MRI is used to confirm the diagnosis and see the full extent of it.

Sam: That makes sense. You'd want a map before you do anything.

Sara: Right. Interestingly, they're often misdiagnosed before birth as something scarier, like a teratoma. But they are benign lesions, which is key.

Sam: That's a huge relief for parents, I'm sure. Okay, so once it's officially diagnosed... what's the game plan? How do we actually manage these?

Sam: So if these things are so complex, how do you even begin to treat them? You can't just... cut them out, right?

Sara: That's a great question! And you're right, resection, or cutting them out, is often a last resort because of the risks. The preferred method is something called sclerotherapy.

Sam: Sclerotherapy. Sounds like something you'd need a textbook to understand.

Sara: Not at all! Think of it this way: we inject a substance that basically irritates the walls of the malformation, causing them to scar and stick together. This shrinks the whole thing.

Sam: Like gluing a leaky balloon shut from the inside!

Sara: Exactly! And we have different types of 'glue'. We prefer an agent called doxycycline because it's super effective, shrinking the lesion by over 80%, and it's really safe.

Sam: So, not all glues are created equal?

Sara: Definitely not. Ethanol is another option, but it has a much higher complication rate. It can even injure nearby nerves, so we avoid it near important structures.

Sam: Okay, so this 'gluing' process sounds great. Is it a permanent fix?

Sara: That's the key issue. These things often re-expand over time. So, patients frequently need repeated treatments throughout their life to manage it.

Sam: And what happens if the injections stop being an option?

Sara: That's when we have to consider resection. But we're incredibly cautious. Attempting to remove these can cause major blood loss and nerve damage—sometimes injuring the facial nerve.

Sam: Wow. So it's a huge decision.

Sara: It is. Resection is really reserved for specific cases, like when the malformation is causing significant problems and sclerotherapy is no longer working.

Sam: So the goal isn't always a perfect removal, but just improving the patient's quality of life.

Sara: Precisely. It's a delicate balancing act. Speaking of different challenges, that brings us to another type of malformation which has its own unique set of problems: Venous Malformations.

Sam: So that makes sense for lymphatic malformations. But let's talk about venous malformations, or VMs. Are they basically just a bundle of problematic veins?

Sara: That's a pretty good summary! They're slow-flow malformations. Think of a spongy mass of abnormal, stretched-out veins where blood can pool and stagnate.

Sam: And stagnant blood sounds like a recipe for trouble.

Sara: It is. This leads to the classic complications: pain, swelling, and sometimes painful little blood clots called phleboliths. In large VMs, it can cause a clotting issue called localized intravascular coagulopathy, or LIC.

Sam: So when it comes to treatment, do you just go in and surgically remove it?

Sara: Great question, but actually, no. Resection is rarely the first step. These malformations are often diffuse, like a tangled web, so it's hard to get the whole thing out.

Sam: You might leave a piece behind and it just grows back?

Sara: Exactly. And the risk of bleeding during surgery is much higher. Here's the key takeaway: the first-line treatment is almost always sclerotherapy.

Sam: Sclerotherapy… what does that involve?

Sara: We inject a special solution directly into the malformation. This causes it to scar up and collapse from the inside, reducing its size and the symptoms.

Sam: So you don't remove it, you just... shut it down. And surgery comes later?

Sara: Sometimes. If there's still a mass after sclerotherapy, resection becomes much safer and more effective. It's all about tackling it in the right order.

Sam: That's a huge difference from the high-flow malformations we're about to discuss, right? Those arteriovenous malformations are a whole different ballgame.

Sam: So that direct connection is the real problem.

Sara: Exactly. It’s called an Arteriovenous Malformation, or AVM. Think of it this way… your circulatory system is like a city's road network.

Sam: Okay, arteries are highways and capillaries are the small local streets?

Sara: Perfect! An AVM is like a construction error where a major highway connects directly to a big return road, with none of the local streets in between.

Sam: So all that high-pressure traffic just slams into the venous system. No wonder that causes problems!

Sara: It’s a vascular short-circuit! And that constant high-pressure flow is why they can get bigger over time.

Sam: What does that look like on a person?

Sara: Well, it can start as just a simple pinkish stain on the skin. A lot of times, it’s mistaken for a birthmark or another type of malformation.

Sam: But as that pressure builds, things get worse...

Sara: Right. The lack of oxygen delivery can lead to pain, ulceration, and even bleeding. It’s a progressive issue. To track it, doctors use something called the Schobinger staging system.

Sam: A staging system? Like for cancer?

Sara: Sort of! Stage I is 'Quiescence'—it's quiet. Stage II is 'Expansion,' where you feel a pulse or thrill. Stage III is 'Destruction,' with skin changes and pain.

Sam: And the last stage?

Sara: Stage IV is 'Decompensation,' which means it's starting to cause heart failure. Now, this staging is crucial for deciding on treatment, but there are also some specific genetic syndromes involved...

Sam: So these overgrowth syndromes are clearly complex. I hear Klippel-Trénaunay and Parkes Weber mentioned a lot. They sound similar, but I bet they're not.

Sara: Not at all! And you're right, people often incorrectly mash their names together. It’s a classic mix-up, but the difference is critical.

Sam: Okay, let's untangle it. First up, Klippel-Trénaunay syndrome, or KTS.

Sara: Think slow-flow. KTS is a combination of capillary, lymphatic, and venous malformations. This leads to overgrowth of a limb, usually a leg, along with a distinct, map-like birthmark.

Sam: A map-like birthmark?

Sara: Yes, we call it a geographic pattern. There’s also often a large, abnormal vein called the marginal vein of Servelle.

Sam: The vein of Servelle? Sounds like a character from a fantasy movie!

Sara: It really does! But it can cause real issues like clots. So management is often conservative—think compressive stockings and aspirin to minimize risks.

Sam: And what about the overgrowth itself?

Sara: If one leg grows much longer, we can use a simple shoe-lift. In some cases, a procedure to slow growth in the longer leg is done to prevent limping and scoliosis.

Sam: Okay, so KTS is slow-flow. What makes Parkes Weber syndrome different?

Sara: Parkes Weber is the polar opposite—it's a fast-flow problem. It's an arteriovenous malformation, or AVM, in an overgrown limb.

Sam: Meaning arteries are connected directly to veins, skipping the capillaries.

Sara: Exactly. The limb is also overgrown with a pink stain, but it feels warm. The key sign is that you can often feel a vibration, called a thrill, or hear a bruit over the area.

Sam: Wow, you can actually feel a vibration? That’s wild.

Sara: It is! And because of that high-speed shunting of blood, it can be much more dangerous, sometimes even causing heart failure in infants. It often requires urgent procedures.

Sam: So the big takeaway is slow-flow versus fast-flow. That really clarifies it. Now, you mentioned heart failure, which brings up a bigger question about systemic effects...

Sam: Okay, that makes so much sense. Now for our last topic, let's switch gears to something really specific—PTEN-associated vascular anomalies.

Sara: Absolutely. This is fascinating stuff. It all starts with a gene called PTEN, which is a tumor suppressor. When there's a mutation here, it can cause something called PTEN Hamartoma Tumor Syndrome, or PHTS.

Sam: I've also heard it called Bannayan-Riley-Ruvalcaba syndrome. That's a mouthful!

Sara: It definitely is! Now, the key thing for our discussion is that over half of people with PHTS get a unique type of fast-flow vascular anomaly. They often look like AVMs on an MRI, but they're different.

Sam: Different how?

Sara: Well, unlike a typical AVM, these can be in multiple spots, and they're usually deep inside a muscle. They also have extra fatty tissue mixed in, which is unusual.

Sam: So if imaging starts the suspicion, how do doctors confirm it?

Sara: It starts with a physical exam. Almost all patients with PHTS have macrocephaly—that's a larger than average head. And all males with the condition have penile freckling.

Sam: Wow. Okay, that's… a very specific sign.

Sara: It is! But it's a huge clue for doctors. They also look for things like thyroid issues or certain types of polyps. For a final confirmation, they can do a biopsy or genetic testing.

Sam: So to recap—it's a genetic syndrome causing unique vascular lesions, and diagnosed using imaging, some very specific physical signs, and genetic tests.

Sara: You've got it. And that's a perfect summary for our whole chat today! It's all about connecting the dots. I had a great time, Sam.

Sam: Me too, Sara! A huge thanks for sharing your expertise. And to our listeners, thanks for tuning into Studyfi Podcast. We'll see you next time!